Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain

References

• Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–976.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Katsarava Z, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15(1):31.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
   Google Scholar
• Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13(5):361–378.
   PubMed Web of Science ®Google Scholar
• Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703–711.
   PubMed Web of Science ®Google Scholar
• Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–162.
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Andrée C, Eurolight Steering Committee. Impact of headache in Europe: a review for the Eurolight project. J Headache Pain. 2008;9(3):139–146.
   PubMed Web of Science ®Google Scholar
• Agosti R. Migraine burden of disease: from the patient's experience to a socio-economic view. Headache. 2018 May;58 Suppl 1:17–32.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–315.
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2014;18(1):385.
   PubMed Web of Science ®Google Scholar
• Messali A, Sanderson JC, Blumenfeld AM, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache. 2016;56(2):306–322.
   PubMed Web of Science ®Google Scholar
• Negro A, Sciattella P, Rossi D, et al. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache centre. J Headache Pain. 2019;20(1):120.
   PubMed Web of Science ®Google Scholar
• Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51(7):1058–1077.
   PubMed Web of Science ®Google Scholar
• Agostoni EC, Barbanti P, Calabresi P, Italian chronic migraine group, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92.
   PubMed Web of Science ®Google Scholar
• American Headache Foundation. The facts about migraine [cited 2020 Nov 23]. Available from: https://americanmigrainefoundation.org/resource-library/migraine-facts/
   Google Scholar
• Delussi M, Vecchio E, Libro G, et al. Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center. BMC Neurol. 2020;20(1):256.
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurol. 2004;62(5):788–790.
   PubMed Web of Science ®Google Scholar
• May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455–464.
   PubMed Web of Science ®Google Scholar
• Torres-Ferrús M, Ursitti F, Alpuente A, et al. From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain. 2020;21(1):42.
   PubMed Web of Science ®Google Scholar
• Buse DC, Greisman JD, Baigi K, et al. Migraine progression: a systematic review. Headache. 2019;59(3):306–338.
   PubMed Web of Science ®Google Scholar
• Manack A, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76(8):711–718.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Migraine chronification. Curr Neurol Neurosci Rep. 2011;11(2):139–148.
   PubMed Web of Science ®Google Scholar
• Scher AI, Midgette LA, Lipton RB. Risk factors for headache chronification. Headache. 2008;48(1):16–25.
   PubMed Web of Science ®Google Scholar
• Foster SA, Chen C-C, Ding Y, et al. Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database. J Med Econ. 2020;23(11):1356–1364.
   PubMed Web of Science ®Google Scholar
• Vo P, Gao W, Zichlin ML, et al. Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain. J Med Econ. 2019;22(9):953–959.
   PubMed Web of Science ®Google Scholar
• Vo P, Gao W, Zichlin ML, et al. Migraine-related healthcare resource use in the emergency department setting: a panel-based chart review in France, Germany, Italy, and Spain. J Med Econ. 2019;22(9):960–966.
   PubMed Web of Science ®Google Scholar
• Henning V, Katsarava Z, Obermann M, et al. Remission of chronic headache: Rates, potential predictors and the role of medication, follow-up results of the German Headache Consortium (GHC) Study. Cephalalgia. 2018;38(3):551–560.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Tepper SJ, Silberstein SD, et al. Reversion from chronic migraine to episodic migraine following treatment with erenumab: results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia. 2021;41(1):6–16.
   PubMed Web of Science ®Google Scholar
• De Matteis E, Affaitati G, Frattale I, et al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci. 2021. DOI:https://doi.org/10.1007/s10072-020-05022-z
   Google Scholar